Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Inclusion Criteria: Patients who meet all of the following criteria are eligible for the study: * Male or female patients aged ≥5.5 years at the time of enrolment * VWD type 1 (baseline von Willebrand factor activity \[VWF:RCo\], \<30 IU/dL), 2A, 2B, 2M, or 3 according to medical history requiring substitution therapy with a VWF-containing product to control bleeding * Currently receiving frequent on-demand treatment with a VWF-containing product * In female patients of child-bearing potential using hormonal contraception, the medication class should remain unchanged for the duration of their study participation * Voluntarily given, fully informed written and signed consent obtained before collection of any patient data Exclusion Criteria: Patients who meet any of the following criteria are not eligible for the study: * Patients currently on prophylaxis for VWD (except for perioperative prophylaxis) as well as patients having received treatment once a month for menstrual bleeding, but not for any other bleeds * Patients whose VWD treatment is planned to be switched from on-demand to prophylactic treatment in the next 6 months * History, or current suspicion, of VWF or FVIII inhibitors * Medical history of a thromboembolic event within 6 months before enrolment * Severe liver or kidney diseases as described in the medical records * Female patients with an existing or suspected pregnancy or who are breast-feeding at the time of enrolment * Change in hormonal contraception …